iCAC Device vs iPredict Eye Screening
AI Verdict
Choose iCAC Device if…
Choose the iCAC Device if your organization seeks to opportunistically identify cardiovascular disease risk in a broad patient population already undergoing routine, non-contrast, non-gated chest CT scans for other indications. This tool is ideal for enhancing early detection efforts by leveraging existing imaging data without requiring additional dedicated scans or patient preparation.
View iCAC Device →Choose iPredict Eye Screening if…
Choose iPredict Eye Screening if your practice focuses on comprehensive, AI-powered screening for common retinal diseases like AMD, DR, and Glaucoma, particularly in primary care or ophthalmology settings. This solution is also well-suited for integrating systemic disease risk prediction (stroke, heart attack) into routine patient assessments, offering a holistic view of patient health.
View iPredict Eye Screening →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | iCAC Device | iPredict Eye Screening |
|---|---|---|
| Pricing | Contact for pricing | Contact for pricing |
| Deployment | Software as a Medical Device (SaMD), integrates with PACS or DICOM router. Cloud-based (via Carebricks platform). | Cloud-based (Software as a Medical Device), accessible in primary care settings, clinics, hospitals, and online for telemedicine and prediction apps. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
iPredict Eye ScreeningTool B explicitly highlights features like 'easy to operate,' 'advanced touchscreen interface,' and 'fast results' (under 5 minutes for test, under 60 seconds for report), indicating a strong focus on user experience and efficiency. Its accessibility across primary care, clinics, hospitals, and telemedicine further suggests broader and simpler adoption for a wider range of healthcare professionals.
Clinical Value
iPredict Eye ScreeningBoth tools are FDA-cleared and address significant health concerns. However, Tool B offers a broader clinical scope by screening for multiple eye conditions (Diabetic Retinopathy, Age-related Macular Degeneration, and Glaucoma) and providing risk prediction for systemic diseases like stroke and heart attack. It also explicitly states high accuracy metrics, averaging approximately 95%.
Pricing & Value
iPredict Eye ScreeningTool B provides greater transparency regarding its pricing model, detailing a 'per patient screening on a Software as a Service (SaaS) model' with an estimated cost range of $10-$20 per patient. This clarity allows potential users to better understand the financial commitment and value proposition compared to Tool A, which only states 'contact for pricing' with no further details.
Enterprise Readiness
iPredict Eye ScreeningTool B explicitly states it is HIPAA-compliant and is designed for accessibility across diverse settings including primary care, clinics, hospitals, and telemedicine services, indicating robust enterprise applicability. While Tool A integrates with PACS/DICOM, its HIPAA compliance and BAA details require direct vendor contact, offering less immediate transparency for enterprise deployment.
Innovation
iPredict Eye ScreeningTool B demonstrates broader innovation by combining AI-powered screening for multiple eye diseases with an online health risk prediction system for systemic conditions like stroke and heart attack, alongside integrated telemedicine services. This multi-faceted approach extends beyond a single opportunistic screening, offering a more comprehensive preventative health platform.
Support & Docs
TieNeither the provided structured facts nor the web search results offer sufficient comparative detail regarding the quality, comprehensiveness, or specific channels for support and documentation for either tool. While Tool B provides general contact information, a direct comparison of dedicated support resources or documentation portals is not possible.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | iCAC Device | iPredict Eye Screening |
|---|---|---|
| Tool Name | iCAC Device | iPredict Eye Screening |
| Company | Bunkerhill Health | iHealthScreen |
| Primary Use Case/Disease Detection | Detects and quantifies coronary artery calcium (CAC) from routine, non-contrast, non-gated chest CT scans, aiding in early cardiovascular disease detection. | AI-powered screening for age-related macular degeneration (AMD), Diabetic Retinopathy (DR), and Glaucoma. Also provides risk prediction for systemic diseases like stroke and heart attack. |
| Key AI-Powered Screenings/Analyses | Estimates presence and quantity of coronary artery calcium (CAC), analyzes routine, non-contrast, non-gated chest CT scans, outputs visual representation and quantitative estimates of CAC burden in Agatston units. | AI-Based Screening for Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), and Glaucoma. Image Analyzer for Retinal Vessel, Retinal Pathology, and OCT Inspector. Online Health Risk Prediction System for Diabetic, Stroke, and Heart Attack patients. |
| Integration Capabilities | Integrates with PACS or DICOM router, integrates with EHRs via the Carebricks platform. | Integrates with EHR and telemedicine services. |
Videos
Demos, reviews, and walkthroughs featuring iCAC Device and iPredict Eye Screening.